$RARE Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -$1.16 up 35.91% YoY
• Reported revenue of $173M up 8.17% YoY
• Ultragenyx reaffirmed full-year 2026 total revenue guidance of $730M to $760M, excluding new product launches; 2027 R&D expenses expected to be less than $350M and SG&A expenses less than $375M.